DNLI
Price
$13.66
Change
-$0.03 (-0.22%)
Updated
May 22 closing price
Capitalization
1.98B
69 days until earnings call
NTLA
Price
$9.15
Change
-$0.31 (-3.28%)
Updated
May 23, 12:59 PM (EDT)
Capitalization
979.9M
69 days until earnings call
Interact to see
Advertisement

DNLI vs NTLA

Header iconDNLI vs NTLA Comparison
Open Charts DNLI vs NTLABanner chart's image
Denali Therapeutics
Price$13.66
Change-$0.03 (-0.22%)
Volume$1.03M
Capitalization1.98B
Intellia Therapeutics
Price$9.15
Change-$0.31 (-3.28%)
Volume$100
Capitalization979.9M
DNLI vs NTLA Comparison Chart
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. NTLA commentary
May 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and NTLA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 23, 2025
Stock price -- (DNLI: $13.66 vs. NTLA: $9.46)
Brand notoriety: DNLI and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 73% vs. NTLA: 73%
Market capitalization -- DNLI: $1.98B vs. NTLA: $979.9M
DNLI [@Biotechnology] is valued at $1.98B. NTLA’s [@Biotechnology] market capitalization is $979.9M. The market cap for tickers in the [@Biotechnology] industry ranges from $307B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, both DNLI and NTLA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 3 TA indicator(s) are bullish while NTLA’s TA Score has 5 bullish TA indicator(s).

  • DNLI’s TA Score: 3 bullish, 7 bearish.
  • NTLA’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than DNLI.

Price Growth

DNLI (@Biotechnology) experienced а -3.53% price change this week, while NTLA (@Biotechnology) price change was +17.15% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.79%. For the same industry, the average monthly price growth was +2.85%, and the average quarterly price growth was -2.67%.

Reported Earning Dates

DNLI is expected to report earnings on Jul 31, 2025.

NTLA is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+0.79% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($1.98B) has a higher market cap than NTLA($980M). NTLA YTD gains are higher at: -18.868 vs. DNLI (-32.974). DNLI (-505.16M) and NTLA (-530.8M) have comparable annual earnings (EBITDA) . DNLI has more cash in the bank: 818M vs. NTLA (504M). DNLI has less debt than NTLA: DNLI (48.6M) vs NTLA (119M). NTLA has higher revenues than DNLI: NTLA (45.6M) vs DNLI (0).
DNLINTLADNLI / NTLA
Capitalization1.98B980M202%
EBITDA-505.16M-530.8M95%
Gain YTD-32.974-18.868175%
P/E RatioN/AN/A-
Revenue045.6M-
Total Cash818M504M162%
Total Debt48.6M119M41%
FUNDAMENTALS RATINGS
DNLI vs NTLA: Fundamental Ratings
DNLI
NTLA
OUTLOOK RATING
1..100
756
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
29
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
4092
PRICE GROWTH RATING
1..100
6463
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
8517

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (29) in the Biotechnology industry is somewhat better than the same rating for DNLI (93). This means that NTLA’s stock grew somewhat faster than DNLI’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DNLI (100). This means that NTLA’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (40) in the Biotechnology industry is somewhat better than the same rating for NTLA (92). This means that DNLI’s stock grew somewhat faster than NTLA’s over the last 12 months.

NTLA's Price Growth Rating (63) in the Biotechnology industry is in the same range as DNLI (64). This means that NTLA’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's P/E Growth Rating (98) in the Biotechnology industry is in the same range as NTLA (100). This means that DNLI’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLINTLA
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
82%
MACD
ODDS (%)
Bearish Trend 1 day ago
86%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
78%
Advances
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 4 days ago
77%
Declines
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 10 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
70%
Bullish Trend 1 day ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TQCCX17.98N/A
N/A
Touchstone Dividend Equity C
EAASX33.64N/A
N/A
Eaton Vance Atlanta Capital SMID-Cap A
DGLCX18.24N/A
N/A
BNY Mellon Global Stock - C
HDSVX16.42N/A
N/A
Hodges Small Intrinsic Value Retail
DCSYX61.27-0.26
-0.42%
Davis Balanced Fund Y